Can I Take Creatine with AOD-9604?

What Is AOD-9604 and Why Does It Appear on Lab Panels?

AOD-9604 is a synthetic peptide corresponding to amino acids 176 to 191 of the C-terminal region of human growth hormone. It was originally developed by Metabolic Pharmaceuticals as an anti-obesity agent and entered phase 2b and phase 3 clinical trials in the early 2000s under the designation MET-88 [1]. Those trials did not produce sufficient weight-loss efficacy to support regulatory approval, and the compound never received FDA clearance for any indication [2].

How AOD-9604 Works

In pre-clinical and early human studies, AOD-9604 appeared to stimulate lipolysis and inhibit lipogenesis through beta-3 adrenergic receptor activity, without producing the insulin-resistance or IGF-1 elevation associated with full-length growth hormone [1]. A 12-week randomized controlled trial (N=300) published in the International Journal of Obesity found that oral AOD-9604 at 1 mg/day produced a statistically non-significant trend toward fat mass reduction compared with placebo, and the compound was characterized as having a favorable safety profile similar to placebo [3].

Current Compounding Status

In the United States, AOD-9604 is available through 503A compounding pharmacies as a research-use peptide. The FDA removed several peptides from the 503A bulk substances list in 2023 and 2024, and practitioners using AOD-9604 in clinical practice operate in a shifting regulatory environment [2]. Patients receiving the peptide should confirm their pharmacy's current compliance status with their prescriber.

Why Labs Matter for AOD-9604 Users

Responsible prescribing of compounded peptides typically includes baseline and follow-up metabolic panels. Serum creatinine and estimated glomerular filtration rate (eGFR) are standard components. That is where creatine supplementation creates a diagnostic complication, not a safety emergency.

How Creatine Affects Serum Creatinine

Creatine is non-enzymatically converted to creatinine in muscle tissue at a rate proportional to the total creatine pool [4]. Supplementing with exogenous creatine increases the intramuscular creatine pool, which increases creatinine production and excretion, raising serum creatinine independently of any change in kidney filtration capacity.

The Magnitude of the Elevation

A 2003 systematic review of creatine supplementation and renal function, published in Medicine and Science in Sports and Exercise, examined nine controlled studies and concluded that creatine supplementation in healthy adults produced small, transient elevations in serum creatinine but did not alter true GFR as measured by inulin clearance or creatinine clearance corrected for intake [4]. Typical serum creatinine increases during a standard loading protocol (20 g/day for 5 to 7 days) range from 0.1 to 0.2 mg/dL above baseline, which translates to roughly a 10 to 20% relative increase for someone starting at 0.9 to 1.0 mg/dL.

Why This Confuses Standard eGFR Equations

The CKD-EPI and MDRD equations use serum creatinine as their primary input [5]. A 20% artificial rise in serum creatinine from creatine loading can shift a person from a calculated eGFR of 95 mL/min/1.73m² down to approximately 78 mL/min/1.73m², crossing the informal threshold that many clinicians flag for further review. That apparent drop reflects the lab artifact, not worsening kidney function.

Cystatin C as a Workaround

Cystatin C-based eGFR equations are not affected by creatine supplementation because cystatin C is produced by nucleated cells at a constant rate and is not derived from dietary creatine or muscle creatine turnover [5]. If a prescriber needs accurate kidney function data while a patient is on creatine, a cystatin C measurement offers a creatinine-independent estimate.

Does Creatine Directly Interact with AOD-9604?

No published pharmacokinetic study has examined creatine and AOD-9604 together. The interaction concern is purely pharmacodynamic in the sense of lab interpretation, not drug-drug interaction in the classical sense.

Pharmacokinetic Pathway Comparison

AOD-9604 is a peptide administered subcutaneously. It is cleaved by circulating peptidases and does not pass through cytochrome P450 hepatic metabolism [1]. Creatine is absorbed in the small intestine via the SLC6A8 creatine transporter and metabolized in muscle and liver through a completely separate enzymatic pathway [6]. There is no shared metabolic enzyme, transporter, or receptor that would produce a classical pharmacokinetic interaction.

Pharmacodynamic Overlap

AOD-9604 targets fat metabolism; creatine targets phosphocreatine resynthesis in skeletal muscle. These mechanisms operate in different tissues through different signaling pathways. A theoretical concern is that increased lean muscle mass from creatine could alter body composition metrics used to assess AOD-9604 efficacy, but no published data confirm this as clinically meaningful.

The One Real-World Signal

The single clinically actionable concern is the lab-interpretation problem described above. A prescriber reviewing a follow-up metabolic panel who sees serum creatinine rise from 0.95 to 1.20 mg/dL may pause or discontinue AOD-9604 if they are unaware the patient started creatine loading in the same interval. That scenario is preventable with one conversation.

Long-Term Renal Safety of Creatine: What the Evidence Actually Shows

Concerns about creatine and kidney damage have circulated in popular fitness media for decades. The primary literature does not support those concerns in healthy adults with normal baseline kidney function.

Key Trial Data

A 2011 randomized controlled trial published in the Journal of the International Society of Sports Nutrition (JISSN) followed 18 healthy male athletes taking creatine monohydrate at 10 g/day for 12 weeks and found no significant change in serum creatinine, BUN, urine albumin, or urinary protein excretion compared to placebo [7]. A 2021 systematic review in Nutrients (17 RCTs, N=1,105 participants) concluded that creatine supplementation at doses of 3 to 20 g/day for up to 52 weeks produced no clinically significant change in kidney function biomarkers in healthy adults [8].

Pre-Existing Kidney Disease Changes the Calculation

The evidence above applies to people with normal baseline renal function. Patients with pre-existing chronic kidney disease (CKD stage 3 or higher, eGFR <60 mL/min/1.73m²) should not begin creatine without explicit nephrology guidance, and they should also discuss AOD-9604 with their prescriber [5]. For this population, both agents require more careful oversight.

What the International Society of Sports Nutrition Says

The ISSN position stand on creatine, last updated in 2017 and reaffirmed in subsequent reviews, states directly: "Creatine supplementation does not adversely affect markers of health in athletes or clinical populations when used within recommended guidelines" [9]. That position stand is the most-cited consensus document on creatine safety and covers more than 500 published studies.

Practical Dosing and Monitoring Guidance

Combining creatine with AOD-9604 is manageable with the right sequence of steps. The following framework reflects standard compounding-peptide prescribing practice and ISSN creatine guidelines.

Step 1: Get Baseline Labs Before Starting Either Agent

Draw a complete metabolic panel (CMP) including serum creatinine, BUN, eGFR, and a urinalysis before initiating AOD-9604 or creatine loading. A true baseline creatinine removes ambiguity from all future lab draws. Most AOD-9604 prescribers will require this anyway.

Step 2: Start AOD-9604 First, Stabilize, Then Add Creatine

AOD-9604 is typically dosed at 250 to 300 mcg subcutaneously once daily in clinical practice [1]. Allowing 4 to 6 weeks on AOD-9604 before beginning creatine gives the prescriber a clean first follow-up metabolic panel. After that panel is documented, starting creatine is straightforward.

If you are already taking both agents simultaneously, disclose creatine use to your prescriber before the next lab draw. Include the dose and how long you have been taking it.

Step 3: Use a Maintenance Dose Rather Than a Loading Protocol

Standard creatine loading (20 g/day for 5 to 7 days) produces the largest acute creatinine spike. A maintenance-only approach (3 to 5 g/day from day one) produces the same saturation of muscle creatine stores over approximately 28 days [9] with a smaller and slower rise in serum creatinine. For patients on peptide protocols with regular lab monitoring, this approach reduces the chance of a confusing lab result.

Step 4: Recheck Labs at 8 to 12 Weeks

A repeat CMP at 8 to 12 weeks after starting creatine, while continuing AOD-9604, provides the comparison data needed to confirm stable kidney function. If serum creatinine has risen, request a cystatin C level to distinguish between a creatine artifact and true GFR change.

Dose Timing

No clinical evidence supports a specific separation window between creatine and AOD-9604 doses. AOD-9604 is typically injected in the morning or evening; creatine can be taken at any time relative to meals and training. Convenience drives the timing decision.

Who Should Be More Cautious

Most healthy adults combining creatine with AOD-9604 face a lab-interpretation issue rather than a safety emergency. Two groups require more careful management.

Patients with Reduced Kidney Reserve

Anyone with a baseline eGFR <60 mL/min/1.73m², a history of nephrolithiasis, or recurrent urinary tract infections should have nephrology input before adding creatine to any peptide regimen. The FDA has not approved AOD-9604 for any indication, and compounded peptides in patients with kidney disease carry additional uncertainty [2].

Patients on Other Nephrotoxic Agents

NSAIDs, contrast dye, aminoglycoside antibiotics, and several antifungals reduce GFR through independent mechanisms [10]. Adding creatine on top of a nephrotoxic agent already in use compounds the lab-interpretation difficulty. In this scenario, cystatin C monitoring is the cleaner path.

Hydration: A Simple Variable That Matters

Creatine increases intramuscular water retention by approximately 1 to 2 liters during the loading phase [9]. This fluid shift can mildly concentrate serum creatinine in the short term if fluid intake does not increase proportionally. Drinking an additional 500 to 750 mL of water daily during creatine initiation partially offsets this effect. It does not eliminate the creatinine signal, but it keeps the elevation closer to the predictable 10 to 20% range rather than pushing it higher.

Summary of the Interaction Classification

No authoritative drug interaction database (Lexicomp, Clinical Pharmacology, or the Natural Medicines database) lists a direct drug-supplement interaction between AOD-9604 and creatine. The concern is a lab-interference phenomenon, not a pharmacological interaction. That distinction matters because it changes the clinical response: the answer is monitoring and communication, not avoidance.

Creatine at 3 to 5 g/day in a person with normal baseline kidney function and no competing nephrotoxic exposures poses no established safety risk alongside AOD-9604. Obtain baseline labs, disclose creatine use to your prescriber, and request cystatin C if a serum creatinine result looks unexpectedly elevated after you start creatine supplementation.